Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation

Although infliximab (IFX) is an efficient therapy for ulcerative colitis (UC) patients, a considerably high rate of therapeutic failures still occurs. This study aimed at a better understanding of IFX pharmacokinetics and pharmacodynamics among clinically-asymptomatic UC patients. This was a multice...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EBioMedicine
Egile Nagusiak: Magro, Fernando, Afonso, Joana, Lopes, Susana, Coelho, Rosa, Gonçalves, Raquel, Caldeira, Paulo, Lago, Paula, de Sousa, Helena Tavares, Ramos, Jaime, Gonçalves, Ana Rita, Ministro, Paula, Rosa, Isadora, Vieira, Ana Isabel, Andrade, Patrícia, Soares, João-Bruno, Carvalho, Diana, Sousa, Paula, Meira, Tânia, Lopes, Joanne, Moleiro, Joana, Dias, Cláudia Camila, Falcão, Amílcar, Geboes, Karel, Carneiro, Fatima
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5514398/
https://ncbi.nlm.nih.gov/pubmed/28629912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2017.06.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak